Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us

 

 

 

Session 24  Oral Abstracts
HIV Drug Resistance: Selection, Persistence, and Impact of Response
Thursday, 10 am - 12:30 pm
Auditorium
10:00 am         96 Structurally-related HIV Co-receptor Antagonists Bind to Similar Regions of CCR5 but Have Differential Activities against UK-427,857-resistant Primary Isolates
Mike Westby*, C Smith-Burchnell, D Hamilton, J Mori, M Macartney, N Robas, B Irvine, M Fidock, F Perruccio, J Mills, K Burt, C Barber, P Stephenson, P Dorr, and M Perros
Pfizer Global Res and Devt, Sandwich, UK
10:15 am         97 Resistance to Enfuvirtide Proceeds through Repeated Selection of HR1 Mutations in Different Env Quasi-species
Beatrice Labrosse*1, L Morand-Joubert2, A Goubard1, S Rochas3, J L Labernardière3, J Pacanowski4, J L Meynard4, A Hance1, F Clavel1, and F Mammano1
1INSERM U552, Hosp Bichat-Claude Bernard, Paris, France; 2Hosp St-Antoine, Paris, France; 3Viralliance, Paris, France; and 4Hosp St-Antoine, Paris, France
10:30 am         98 K65R and T215Y Are Not Present on the Same Viral Genome in Plasma Samples with Both Mutations Detected by Population Sequencing
Urvi Parikh*1, D Barnas1, C Bixby1, H Faruki2, and J Mellors1
1Univ of Pittsburgh, PA, USA and 2Lab Corp of America, Research Triangle Park, NC, USA
10:45 am         99 Selection of Resistance Mutations in Children Receiving Prophylaxis with Lamivudine or Nevirapine for the Prevention of Postnatal Transmission of HIV
Marina Giuliano*1, C Galluzzo1, E Germinario1, R Amici1, M Pirillo1, L Bassani1, J Vyankandondera2, F Mmiro3, P Okong4, and S Vella1
1Inst Superiore di Sanita, Rome, Italy; 2Ctr Hosp de Kigali, Rwanda; 3Mulago Hosp, Kampala, Uganda; and 4St Francis Hosp, Nsambya, Kampala, Uganda
11:00 am      100 Resistance Emerges in the Majority of Women Provided Intrapartum Single-dose Nevirapine
Jeffrey Johnson*1, J F Li1, L Morris2, N Martinson3,5, G Gray4, J McIntyre4, and W Heneine1
1CDC, Atlanta, GA, USA; 2Natl Inst for Communicable Diseases, Johannesburg, South Africa; 3Univ of the Witwatersrand, Johannesburg, South Africa; 4Univ of the Witwatersrand, Johannesburg, South Africa; and 5Johns Hopkins Univ, Baltimore, MD, USA
11:15 am      101 Persistence of NNRTI-r Resistant Variants after Single-dose Nevirapine in HIV-1 Subtype-C-infected Women
Sarah Palmer*1, V Boltz1, F Maldarelli1, N Martinson2,3, G Gray3, J McIntyre3, J Mellors4, L Morris5, and J Coffin1
1NCI-Frederick, NIH, DHHS, MD, USA; 2Johns Hopkins Univ, Baltimore, MD, USA; 3Chris Hani Baragwanath Hosp, Univ of the Witwatersrand, Johannesburg, South Africa; 4Univ of Pittsburgh, PA, USA; and 5Natl Inst for Communicable Diseases, Johannesburg, South Africa
11:30 am      102 Sensitive Real-Time PCR Quantification of 103N Resistance Mutants following Single-dose Treatment with Nevirapine
Shayne Loubser*1, P Balfe2,5, G Sherman3, S Jones3, S Cohen1, L Kuhn4, S Hammer4, and L Morris1
1Natl Inst for Communicable Diseases, Johannesburg, South Africa; 2Univ of Birmingham Med Sch, UK; 3Natl Hlth Lab Svcs, Univ of the Witwatersrand, Johannesburg, South Africa; 4Columbia Univ, New York, NY, USA; and 5Columbia Univ, New York, NY, USA
11:45 am      103 Effectiveness of Single-dose Nevirapine in a Second Pregnancy
Neil Martinson*1,2, L Pumla2, L Morris3, M Ntsala3, A Puren3, C Chezzi3, P Dhlamini2, S Cohen3, G Gray2, J Steyn2, and J McIntyre2
1Johns Hopkins Univ, Baltimore, MD, USA; 2Univ of the Witwatersrand, South Africa; and 3Natl Inst for Communicable Diseases, Johannesburg, South Africa
12:00 pm      104 Effect of Baseline Genotype on Response to Tipranavir/ritonavir (TPV/r) Compared with Standard-of-care Comparator (CPI/r) in Treatment-experienced Patients: The Phase 3 RESIST-1 and -2 Trials
J Schapiro*1, P Cahn2, B Trottier3, F Antunes4, D Jayaweera5, J Gerstoft6, D Norris7, D Cooper8, C Hicks9, S McCallister10, D Hall10, H Valdez10, D Neubacher10, V Kohlbrenner10, and D Mayers10
1Ctr for AIDS Res, Stanford Univ Med Sch, CA, USA; 2Fndn Huésped, Buenos Aires, Argentina; 3Clin Med l' Actuel, Montreal, Canada; 4Hosp Santa Maria, Lisbon, Portugal; 5Jackson Med Ctr, Miami, FL, USA; 6Natl Univ Hosp, Rigshospitalet, Copenhagen, Denmark; 7Ctr for Quality Care, Tampa, FL, USA; 8St Vincent's Hosp, Univ of New South Wales, Sydney, Australia; 9Duke Univ Med Ctr, Durham, NC, USA; and 10Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA
12:15 pm      105 Prediction of Early HIV-1 RNA Reduction in the Jaguar Study Using Phenotypic Susceptibility to Didanosine
Michael Bates*1, P Flandre2, K Ryan3, A G Marcelin4, J F Maa3, D Seekins3, C Chappey1, V Calvez4, M C Bernard5, and J M Molina6
1ViroLogic, Inc, South San Francisco, CA, USA; 2INSERM U472, Villejuif, France; 3Bristol-Myers Squibb, Plainsboro, NJ, USA; 4Hosp Pitie-Salpetriere, Paris, France; 5Bristol-Myers Squibb, Rueil-Malmaison, France; and 6Hosp St Louis, Paris, France